GlassScriptPhysician profile
Mary A High
NPI 1457350019
$8,485.61
in general payments reported to CMS, 2019-2025
36 companies · $1,673 in 2025
The $1,673 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,599 · 2022: $1,835 · 2023: $1,532 · 2024: $1,847 · 2025: $1,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,052.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,569.12 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,542.04 | 2021-2025 | |
| Lilly USA, LLC | $816.29 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $703.25 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $615.15 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $390.73 | 2021-2025 | |
| Axsome Therapeutics, INC. | $364.92 | 2022-2025 | Sunosi |
| Astellas Pharma US INC | $321.97 | 2022-2025 | Veozah |
| Merck Sharp & Dohme LLC | $199.77 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $190.22 | 2022-2025 | Rexulti |
| Abbott Laboratories | $181.54 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.05 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $173.67 | 2023-2025 | Quviviq, Quviviq |
| Biohaven Pharmaceuticals, INC. | $161.44 | 2021 | |
| Medtronic, INC. | $132.74 | 2022-2024 | Intellis Adaptivestim, Closurefast |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary High listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.